Management of cutaneous discomfort in patients with scleroderma: a clinical trial

  • M. Muratore | davide.carati@ekubergpharma.com Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • L. Quarta Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • L. Raho Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • D. Costanza Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • S. Frisenda Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • F. Calcagnile Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • A. Grimaldi Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • E. Quarta Department of Rheumatology, “A. Galateo” Hospital, San Cesario di Lecce (LE), Italy.
  • D. Carati Research and Development Department, Ekuberg Pharma srl, Martano (LE), Italy.
  • M. Guido Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
  • A. Zizza Institute of Clinical Physiology, National Research Council, Lecce, Italy.
  • G. Alessandrini Dermatologist, Ugento (LE), Italy.

Abstract

Systemic sclerosis (scleroderma) is a disease of unknown cause, the hallmark of which is induration of the skin. This bad condition of the skin influences negatively the quality of life of patients with scleroderma. The aim of the study was to verify the efficacy of two formulations, specifically designed to wash, moisturize and soothe the scleroderma skin. An independent, randomized, double blind, controlled trial was conducted in the Department of Rheumatology of “A. Galateo” Hospital in San Cesario di Lecce. Forty-six women affected by scleroderma, and treated with Iloprost every month, were divided into two groups: group 1 followed a specific treatment with cleansing formulation only, group 2 followed a combined treatment with the cleansing solution and the moisturizing solution. In addition, a third group was evaluated: 14 women, who did not undergo intravenous Iloprost therapy, were treated simultaneously with the cleansing formulation and the moisturizing formulation. The three treatments lasted for 4 weeks. Reduction in trans epidermal water loss (TEWL), increase in moisturization of the stratum corneum, reduction in Skin Score and improvement in quality of life were assessed. Very significant improvement in quality of life occurred in each group. Group 2 obtained very significant improvement in hydration and reduction in skin score and TEWL. The study showed that the daily use of both formulations proved to be effective in washing, hydrating and soothing the skin of patients with scleroderma, especially in association with Iloprost therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2013-12-18
Info
Issue
Section
Articles
Keywords:
Systemic sclerosis, Skin care, Trans epidermal water loss (TEWL) test.
Statistics
  • Abstract views: 2693

  • PDF: 694
How to Cite
Muratore, M., Quarta, L., Raho, L., Costanza, D., Frisenda, S., Calcagnile, F., Grimaldi, A., Quarta, E., Carati, D., Guido, M., Zizza, A., & Alessandrini, G. (2013). Management of cutaneous discomfort in patients with scleroderma: a clinical trial. Reumatismo, 65(5), 240-247. https://doi.org/10.4081/reumatismo.2013.240